“The FDA official responded, “You all know that as background, I’m a professor and I’m a practicing [hematology-oncology] doctor. I do miss my clinic and I miss teaching, and I miss being able to run my podcast and speak freely.”
statnews.com/2026/03/06/fda-…
We've unveiled our new five-year strategy and shared preliminary Q4 and FY2025 global net product revenues, 2026 pipeline goals and product sales outlook.
Read the press release: bit.ly/4jxw4IU
Join our live #JPM26 webcast tomorrow at 9 AM PT: bit.ly/4srb8ax
For Alzheimer's disease, it's no longer a debate of amyloid (Aβ) versus tau. They are interactive drivers and this new, optimistic review maps out a path towards disease-halting therapies @CellCellPresscell.com/cell/fulltext/S0092…
Excited to share our new work on immune aging! We explored whether the liver could serve as a temporary "factory" to produce immune factors that decline with aging, potentially helping to rejuvenate aged immunity. @mircoscopy.
“For decades, the U.S. has been the pinnacle of global science. Now experts fear it may have lost some of its luster, and that budding international researchers won’t… take their next career step in the U.S.”
Not MAGA or MAHA.
A major milestone for genetic medicines!
First-ever in vivo genetic correction of a human disease!
Amazing result for science, medicine, and patients!
So proud of the Beam team! globenewswire.com/news-relea…
$SGMO. Recalled $PFE handed $ROIV biotech gift of year in 2023, think they might do it again in 2025, this time for $SGMO. If both Fabry and HemoA deals go through for $SGMO, it could be a $10 stock.
Barclays: $SGMO says inbound interest for #HemoA GT program and would transfer the program from $PFE to new partner
Hemo GT #UPDATE here likely #April#Fabry deal announcement likely in Q1
#competitive#bidding
upfront payment ~ $250M , milestones and double digit royalties